The ophthalmic drugs contract manufacturing market is estimated to be worth USD 1.7 billion in 2030.

Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.”

The report features an extensive study of the contract services market for ophthalmic products and solutions. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:
 A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters.
 A competitiveness analysis of prominent contract manufacturers, featuring insightful pictorial summaries and representations.
 Elaborate profiles of key players that offer a diverse range of capabilities for the contract development, manufacturing and packaging of ophthalmic drug products.
 A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products.
 An estimate of the overall, annual capacity for manufacturing ophthalmic APIs and drug FDFs based on data reported by industry stakeholders in the public domain.
 An informed estimate of the annual clinical and commercial demand for ophthalmic APIs and drug FDFs.
 A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, including a Harvey ball analysis highlighting the relative effect of each SWOT parameter on the overall industry.

Leave a Reply

Your email address will not be published. Required fields are marked *

The ophthalmic drugs contract manufacturing market is estimated to be worth USD 1.7 billion in 2030,

Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.”

The report features an extensive study of the contract services market for ophthalmic products and solutions. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:
 A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters.
 A competitiveness analysis of prominent contract manufacturers, featuring insightful pictorial summaries and representations.
 Elaborate profiles of key players that offer a diverse range of capabilities for the contract development, manufacturing and packaging of ophthalmic drug products.
 A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products.
 An estimate of the overall, annual capacity for manufacturing ophthalmic APIs and drug FDFs based on data reported by industry stakeholders in the public domain.
 An informed estimate of the annual clinical and commercial demand for ophthalmic APIs and drug FDFs.
 A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, including a Harvey ball analysis highlighting the relative effect of each SWOT parameter on the overall industry.

Leave a Reply

Your email address will not be published. Required fields are marked *